Rituximab treatment in myasthenia gravis
Myasthenia gravis (MG) is a chronic autoimmune disease mediated by antibodies against post-synaptic proteins of the neuromuscular junction. Up to 10%–30% of patients are refractory to conventional treatments. For these patients, rituximab has been used off-label in the recent decades. Rituximab is a...
Shranjeno v:
| Principais autores: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2023-10-01
|
| Serija: | Frontiers in Neurology |
| Teme: | |
| Online dostop: | https://www.frontiersin.org/articles/10.3389/fneur.2023.1275533/full |
| Oznake: |
Brez oznak, prvi označite!
|